---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-017166"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T00:45:30.957296+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MaxCyte Q3 revenue up 5% to $10.6M; core business grows 22%; net loss widens to $6.4M

## Summary
- Total revenue $10.6M (+5% YoY); core business revenue $9.9M grew 22% led by cell therapy +27%.
- Net loss widened to $6.4M from $2.7M; EBITDA loss $7.1M vs $2.4M loss a year ago.
- Cash and equivalents $232.9M; operating expenses rose to $17.0M from $11.6M on staffing and R&D.
- Reiterated FY2022 guidance: core revenue growth ~30%, SPL program revenue ~$4.0M.
- Cell therapy revenue $7.9M (+27%), drug discovery $2.0M (+4%); SPL revenue fell 62% to $0.8M.

## SEC filing metadata
- accession: 0001558370-22-017166
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837022017166/0001558370-22-017166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837022017166/mxct-20221109x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-017166
- JSON: https://secwatch.observer/filing/0001558370-22-017166.json
- Plain text: https://secwatch.observer/filing/0001558370-22-017166.txt

## Key facts
- Earnings Releases
  MAXCYTE, INC. reported financial results for the nine months ended September 30, 2022.
  - Period: the nine months ended September 30, 2022
  - Result: reported results
  source text: announcing its financial results for the quarter and nine months ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1287098/000155837022017166/0001558370-22-017166-index.htm
- Earnings Releases
  MAXCYTE, INC. reported the third quarter ended September 30, 2022 results: revenue $10.6 million, net income $6.4 million. Guidance reaffirmed.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $10.6 million
  - Net income: $6.4 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenue of $10.6 million in the third quarter of 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1287098/000155837022017166/0001558370-22-017166-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.